Gene therapy trial hopes to strengthen hearts in rare genetic disease
Disease control
Not yet recruiting
This early-stage trial tests a single infusion of AFTX-201, a gene therapy designed to help heart muscle cells produce a missing protein in people with dilated cardiomyopathy caused by a BAG3 gene mutation. About 22 adults with moderate heart failure will be enrolled to check saf…
Phase: PHASE1, PHASE2 • Sponsor: Affinia Therapeutics • Aim: Disease control
Last updated May 26, 2026 11:36 UTC